Epicrispr's epigenetic editor EPI-321 shows a 3% gain in muscle volume in FSHD patients at 6 months, alongside one case of severe liver enzyme elevation.
Epicrispr Biotechnologies has bagged a $90-million series C that will help the biotech move its lead epigenetic therapy into pivotal testing for facioscapulohumeral muscular dystrophy (FSHD).
The Series C financing will be used to advance Epicrispr's lead epigenetic therapy for facioscapulohumeral muscular dystrophy toward pivotal clinical studies.
Epicrispr has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
Epicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an early-phase facioscapulohumeral muscular dystrophy (FSHD) prospect.
Epicrispr has raised a Series C round after sharing promising early data for EPI-321, a potential new way to treat facioscapulohumeral muscular dystrophy.
Epicrispr Biotechnologies has completed enrolment and dose escalation in the first-in-human trial of EPI-321, an epigenetic CRISPR-based therapy for facioscapulohumeral muscular dystrophy (FSHD).
Epicrispr Biotechnologies announced that its first trial testing EPI-321, which targets the underlying cause of this form of muscular dystrophy, is fully enrolled, and dosing of participants is now also done.
Interim phase 1/2 data showed increased lean muscle volume and a favorable safety profile following a single dose of EPI-321 in the first three evaluable patients with facioscapulohumeral muscular dystrophy.
Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass in three patients with facioscapulohumeral muscular dystrophy, a clinical first for the debilitating disease with no approved treatments.
Epicrispr's lead candidate, EPI-321, is an AAV-delivered, one-time gene-modulating treatment designed to silence faulty DUX4 gene expression without altering the underlying DNA sequence. The treatment is being studied in a Phase I/II trial involving adults with FSHD.
It’s a crucial moment for the cell and gene therapy field. At the American Society of Gene & Cell Therapy’s annual meeting, several trends emerged: In vivo CAR-T is everywhere, CRISPR comes for Alzheimer’s and FDA officials took the stage.
CEO Amber Salzman walks us through the science, which allows the company to dial up or dial down genes of interest rather than making a cut into the DNA.
For pioneering treatments that control gene expression to help people with neuromuscular disease
Epicrispr’s epigenetic editing platform is designed to activate or repress gene targets without cutting DNA, offering a potentially safer and more durable approach to treating diseases caused by aberrant genes.
In this Q&A, Amber Salzman, CEO of Epicrispr Biotechnologies, explains how applying the win ratio in FSHD could transform the way investigators evaluate therapeutic impact, enhance statistical efficiency, and advance the design of trials that better reflect the lived realities of patients.
Recorded at Fierce Biotech Week, this panel featuring leaders from past Fierce 15 winners, including Epicrispr's CEO Amber Salzman, digs into timelines, partnerships, what's hype, what's signal and how teams are pressure-testing their models in today's market.
Epicrispr recently used Springbok Analytics’ AI-driven platform in our first-in-human clinical trial, and the partnership illustrates how emerging imaging analytics can be integrated into clinical trials to generate reproducible, regulator-ready data at scale.
At the LSX World Congress USA in Boston this week, investors and biotech CEOs, including Amber Salzman of Epicrispr, discussed what factors are holding back precision medicine.
Epicrispr Biotechnologies has dosed the first patient in its global first-in-human clinical trial of EPI-321, the first investigational therapy designed to silence DUX4 expression through epigenetic modulation for facioscapulohumeral muscular dystrophy (FSHD).
Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about epigenetic editing, working with the FDA, using AI for clinical endpoints, and more.
CEO Amber Salzman describes how Epicrispr Biotechnologies will utilize AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy.
Recent in vivo studies show that preserving DNA sequences while altering methylation patterns can be safe and efficacious, encouraging clinical aspirations.
Epicrispr has been named to Fierce Biotech’s 2023 “Fierce 15” list, designating it as one of the most outstanding early-stage biotechnology companies in the industry.
Epicrispr is championing the development of epigenetic therapies to modify gene expression, targeting a range of diseases not currently addressable with existing genetic medicines.
Focused in the field of epigenetics, U.S.-based Epicrispr was spun out of Stanford University in 2018. The startup has built the Gene Expression Modulation System (GEMS), its platform technology, to treat a number of diseases.
The biotechnology company Epicrispr presented preclinical data supporting the potential clinical progress of EPI-321 in treating facioscapulohumeral muscular dystrophy (FSHD).
The San Francisco-based company has taken a step forward with proof of concept for its ‘switch on or switch off’ approach to gene regulation via non-cutting CRISPR molecules.
To overcome the obstacles for CRISPR-Cas9 gene editing, the startup Epicrispr was launched in July 2022 with an impressive Series A round worth $55 million.
Epicrispr, founded by Stanford bioengineer Stanley Qi, builds pipeline with tiniest Cas protein, epigenetic modulators, a platform that combines them, and proceeds from $55M Series A.
Epicrispr is funded by Horizons Ventures and led by Amber Salzman, who has headed multiple genetic medicine companies, most recently Adverum Biotechnologies.
Controlling the epigenetics of a patient, figuring out what genes are expressed and understanding their level of expression, is at the center of a new company founded by Stanley Qi.
Epicrispr is controlling target gene expression using single vectors that combine its highly compact Cas protein with guide RNAs and epigenetic modulators.
A former doctoral candidate in CRISPR pioneer Jennifer Doudna’s lab founded a new biotech seeking to wade into “epigenetics-level gene editing,” and has now secured enough capital to do just that.
